{"title": "Active Clinical Trials and Research Studies", "author": null, "url": "https://www.hopkinsallchildrens.org/Services/Cancer-Institute/Programs-and-Services/Center-for-Cell-and-Gene-Therapy-for-Non-Malignant/Active-Clinical-Trials-and-Research-Studies", "hostname": "hopkinsallchildrens.org", "description": "A list of active clinical trials and research studies available or anticipated in the Center for Cell and Gene Therapy for Non-malignant Conditions.", "sitename": "hopkinsallchildrens.org", "date": "2023-01-01", "cleaned_text": "The following are the active clinical trials currently available or anticipated in the Center for Cell and Gene Therapy for Non-malignant Conditions. More information is available at [ClinicalTrials.gov](https://www.clinicaltrials.gov/ct2/results?cond=&term=chellapandian+tcr&cntry=&state=&city=&dist=&Search=Search). - TCR T-cell and CD19 B-cell Depleted Haploidentical Hematopoietic Cell Transplantation in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children (HAP-PID). - TCR T-cell and CD19 B-cell Depleted Haploidentical Hematopoietic Cell Transplantation in the Treatment of Non-Malignant Hematological Disorders in Children (HAP-HEM). - Cell Processing for Hematopoietic Stem Cell Infusion Using the Miltenyi CliniMACS CD34 System. - MB107-XSCID-002: A Phase 2, Single- Arm, Open- Label, Multicenter Trial to Assess the Safety and efficacy of MB-107 in Newly Diagnosed Infants with X-Linked Severe Combined Immunodeficiency (anticipated Spring 2021). - MB-207-003: A Phase 2, Single- Arm, Open- Label, Multicenter Trial to Assess the Safety and efficacy of MB-107 in previously Treated Infants with X-Linked Severe Combined Immunodeficiency (anticipated Spring 2021). - PBMTC 01-0923: A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regimen. - LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis. - [6901](https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rarediseasesnetwork.org%2Fcms%2Fpidtc%2FGet-Involved%2FStudies%2F6901&data=04%7C01%7Cklaform1%40jhmi.edu%7C611395a305f541ac90cb08d8b7d236f7%7C9fa4f438b1e6473b803f86f8aedf0dec%7C0%7C0%7C637461460771054193%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=stoj%2BiV%2B0ARW8fnicJlyKN12n9fvdGJCUzGzlrV%2Bo%2BM%3D&reserved=0): A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with Severe Combined Immune Deficiency Disorders - [6902](https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rarediseasesnetwork.org%2Fcms%2Fpidtc%2FGet-Involved%2FStudies%2F6902&data=04%7C01%7Cklaform1%40jhmi.edu%7C611395a305f541ac90cb08d8b7d236f7%7C9fa4f438b1e6473b803f86f8aedf0dec%7C0%7C0%7C637461460771064190%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=QC4rSZWgjDiU9HznOroz2HbeWMzUz50QFs6iQNfzrrg%3D&reserved=0): A Retrospective and Cross-Sectional Analysis of Patients Treated for Severe Combined Immune Deficiency (1968-2010) - [6903](https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rarediseasesnetwork.org%2Fcms%2Fpidtc%2FGet-Involved%2FStudies%2F6903&data=04%7C01%7Cklaform1%40jhmi.edu%7C611395a305f541ac90cb08d8b7d236f7%7C9fa4f438b1e6473b803f86f8aedf0dec%7C0%7C0%7C637461460771074183%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=YtjE2o61dLBIQcaBMkQicKOpw2CT93%2BAG9ZL6nJGDio%3D&reserved=0): Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 - [6904](https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.rarediseasesnetwork.org%2Fcms%2Fpidtc%2FGet-Involved%2FStudies%2F6904&data=04%7C01%7Cklaform1%40jhmi.edu%7C611395a305f541ac90cb08d8b7d236f7%7C9fa4f438b1e6473b803f86f8aedf0dec%7C0%7C0%7C637461460771074183%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=gbZN8kR%2Fd3Vp2PH6RNfEylI46IhxzWalrPmAOj%2FZyK0%3D&reserved=0): Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 - 6905: A phase II randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR+/CD19+ depleted transplantation (CSIDE). For more information about participating in "}